"Fluoroquinolones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of QUINOLONES with at least one fluorine atom and a piperazinyl group.
| Descriptor ID |
D024841
|
| MeSH Number(s) |
D03.633.100.810.835.322
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fluoroquinolones".
Below are MeSH descriptors whose meaning is more specific than "Fluoroquinolones".
This graph shows the total number of publications written about "Fluoroquinolones" by people in this website by year, and whether "Fluoroquinolones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 2 | 0 | 2 |
| 2005 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluoroquinolones" by people in Profiles.
-
Zgurskaya HI, Walker JK, Parks JM, Rybenkov VV. Multidrug Efflux Pumps and the Two-Faced Janus of Substrates and Inhibitors. Acc Chem Res. 2021 02 16; 54(4):930-939.
-
Barot M, Gokulgandhi MR, Agrahari V, Pal D, Mitra AK. Monocarboxylate transporter mediated uptake of moxifloxacin on human retinal pigmented epithelium cells. J Pharm Pharmacol. 2014 Apr; 66(4):574-83.
-
Pettey JH, Mifflin MD, Kamae K, McEntire MW, Pettey DH, Callegan MC, Brown H, Olson RJ. The impact of short-term topical gatifloxacin and moxifloxacin on bacterial injection after hypodermic needle passage through human conjunctiva. J Ocul Pharmacol Ther. 2013 Jun; 29(5):450-5.
-
Callegan MC, Novosad BD, Ramadan RT, Wiskur B, Moyer AL. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones. Adv Ther. 2009 Apr; 26(4):447-54.
-
Bratzler DW, Ma A, Nsa W. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project. Clin Infect Dis. 2008 Dec 01; 47 Suppl 3:S193-201.
-
Wiskur BJ, Robinson ML, Farrand AJ, Novosad BD, Callegan MC. Toward improving therapeutic regimens for Bacillus endophthalmitis. Invest Ophthalmol Vis Sci. 2008 Apr; 49(4):1480-7.
-
Ali T, Greenfield RA, Scofield H, Bronze MS. Gatifloxacin-associated hypoglycemia. J Okla State Med Assoc. 2007 Nov; 100(11):425-8.
-
Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Chest. 2007 Feb; 131(2):466-73.
-
Chang NN, Murray CK, Houck PM, Bratzler DW, Greenway C, Guglielmo BJ. Blood culture and susceptibility results and allergy history do not influence fluoroquinolone use in the treatment of community-acquired pneumonia. Pharmacotherapy. 2005 Jan; 25(1):59-66.
-
Callegan MC, Ramirez R, Kane ST, Cochran DC, Jensen H. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens. Adv Ther. 2003 Sep-Oct; 20(5):246-52.